Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Ruhstaller

Showing results (11-20 of 71) with videos related to

Pageof 8
Sort By:
Trials|July 8, 2020
Eurythmy therapy versus slow movement fitness in the treatment of fatigue in metastatic breast cancer patients: study protocol for a randomized controlled trialDelphine Meier-Girard, Karin Ribi, Gisa Gerstenberg, et al.
Oncotarget|February 4, 2016
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patientsSarah Cattin, Benoît Fellay, Sylvain Pradervand, et al.
Breast (Edinburgh, Scotland)|April 18, 2020
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancerAngela Fischer Maranta, Simon Broder, Constanze Fritzsche, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 17, 2009
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?Richard Cathomas, Dieter Köberle, Thomas Ruhstaller, et al.
Journal of Medical Case Reports|December 1, 2009
Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case reportChristian Spirig, Aurelius Omlin, Giannicola D'Addario, et al.
BMC Cancer|March 28, 2013
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivorsArnoud J Templeton, Beat Thürlimann, Michael Baumann, et al.
Plos One|April 18, 2015
Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 studyZsuzsanna Varga, Estelle Cassoly, Qiyu Li, et al.
Cancer Reports (Hoboken, N.J.)|September 28, 2021
Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methodsFelicitas Hitz, Karin Ribi, Gudela Grote, et al.
BMC Cancer|February 13, 2020
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99Serenella Eppenberger-Castori, Dirk Klingbiel, Thomas Ruhstaller, et al.
Therapeutic Advances in Medical Oncology|January 15, 2019
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scoresPiera Gargiulo, Daniel Dietrich, Richard Herrmann, et al.
Pageof 8

Showing results (11-20 of 71) with videos related to

Sort By:
Pageof 8
Trials|July 8, 2020
Eurythmy therapy versus slow movement fitness in the treatment of fatigue in metastatic breast cancer patients: study protocol for a randomized controlled trialDelphine Meier-Girard, Karin Ribi, Gisa Gerstenberg, et al.
Oncotarget|February 4, 2016
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patientsSarah Cattin, Benoît Fellay, Sylvain Pradervand, et al.
Breast (Edinburgh, Scotland)|April 18, 2020
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancerAngela Fischer Maranta, Simon Broder, Constanze Fritzsche, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 17, 2009
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?Richard Cathomas, Dieter Köberle, Thomas Ruhstaller, et al.
Journal of Medical Case Reports|December 1, 2009
Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case reportChristian Spirig, Aurelius Omlin, Giannicola D'Addario, et al.
BMC Cancer|March 28, 2013
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivorsArnoud J Templeton, Beat Thürlimann, Michael Baumann, et al.
Plos One|April 18, 2015
Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 studyZsuzsanna Varga, Estelle Cassoly, Qiyu Li, et al.
Cancer Reports (Hoboken, N.J.)|September 28, 2021
Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methodsFelicitas Hitz, Karin Ribi, Gudela Grote, et al.
BMC Cancer|February 13, 2020
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99Serenella Eppenberger-Castori, Dirk Klingbiel, Thomas Ruhstaller, et al.
Therapeutic Advances in Medical Oncology|January 15, 2019
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scoresPiera Gargiulo, Daniel Dietrich, Richard Herrmann, et al.
Pageof 8